Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review-Reference-Cited by-同舟云学术

Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review

Published:2023-09-04 Issue:9 Volume:23 Page:1017-1026
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Parra Ana¹,Hernández Claudia¹,Prieto-Pinto Laura²

Affiliation:

1. Evidence-Based Medicine Department, NeuroEconomix, Bogotá, Colombia

2. Evidence Generation Lead. Productos Roche S.A. Bogotá, Bogotá, Colombia

Funder

Roche, Colombia

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2023.2249232

Reference49 articles.

1. Organización Mundial de la Salud/OMS. Cáncer [Internet]. 2018. p. 1–7. Available from: https://www.who.int/es/news-room/fact-sheets/detail/cancer

2. World Health Organization. Globocan 2020 [Internet]. WHO Chron. 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf

3. The Lancet Commission on cancer and health systems: harnessing synergies to achieve solutions

4. The cost of cancer in Europe 2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stick With Intravenous or Give Subcutaneous a Shot? Time and Other Considerations When Evaluating Cancer Drug Formulations;JCO Oncology Practice;2024-08-02

2. Evaluating unmet needs in large-volume subcutaneous drug delivery: U.S. payer perspectives on a novel, large-volume on-body delivery system;Current Medical Research and Opinion;2024-05-17